The board of directors of AbbVie (NYSE:ABBV), a biopharmaceutical company, declared on Thursday its quarterly dividend of USD0.96 per share of its stock.
This 35% higher cash dividend is due on 15 May 2018 to stockholders of record at the close of business on 13 April 2018.
Since the company's inception in 2013, AbbVie has increased its dividend by 140 percent.
In addition, the company has approved a new USD10bn stock repurchase programme in open market or private transactions, has no time limit and may be discontinued at any time. The purchases may be made from time to time in management's discretion.
Bruker Corporation to acquire ELITechGroup for EUR870m, strengthening MDx portfolio
Perrigo announces quarterly dividend increase
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva
Biosenic finalises agreement with Phebra for oral arsenic troxide development